期刊文献+

血管内皮生长因子及其受体在肿瘤治疗中的应用 被引量:1

The application of VEGF and VEGFR in treatment for tumor
原文传递
导出
摘要 通过血管内皮生长因子(VEGF)和血管内皮生长因子受体(VEGFR)来治疗肿瘤,可以由基因和细胞分子水平等多种途径获得,例如,可用单克隆抗体中和靶目标、或用小分子抑制剂抑制靶目标信号传导、或通过改变靶目标基因表达等。抗VEGF及其VEGFR可以单独应用,也可与抗其他生长因子、放疗等其他方法相结合,来增加抑制肿瘤生长的效果。 To treat tumor by vascular endothelial growth factor and its receptor may approach by gene and cell molecular level ,for instance, monoclonal antibody neutralize target objective, micromolecule inhibitor to inhibit target objective signal conduction,change target gene expression and so on. Resisting vascular endothelial growth factor and its receptor may be applied alone, also may combine with anti-other-growth factor or radiotherapy to increase the effect of inhibiting tumor growth.
出处 《国际肿瘤学杂志》 CAS 2009年第10期768-771,共4页 Journal of International Oncology
关键词 放射疗法 诊断 抗体 肿瘤 Radiotherapy Diagnosis Antibodies Neoplasms
  • 相关文献

参考文献2

二级参考文献88

  • 1郭晨莹,王恒,蔺亚晖,蔡启良.应用PAMAM dendrimers作为DNA运送载体的体外研究[J].生物化学与生物物理进展,2004,31(9):804-811. 被引量:5
  • 2[1]Cancer facts and figures 2006.Atlanta:American Cancer Society,2006.Available URL from:http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf
  • 3[2]Obrand DI,Gordon PH.Incidence and patterns of recurrence following curative resection for colorectal carcinoma.Dis Colon Rectum 1997; 40:15-24
  • 4[3]Petrelli N,Douglass HO Jr,Herrera L,Russell D,Stablein DM,Bruckner HW,Mayer RJ,Schinella R,Green MD,Muggia FM.The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma:a prospective randomized phase Ⅲ trial.Gastrointestinal Tumor Study Group.J Clin Oncol 1989; 7:1419-1426
  • 5[4]Poon MA,O'Connell MJ,Moertel CG,Wieand HS,Cullinan SA,Everson LK,Krook JE,Mailliard JA,Laurie JA,Tschetter LK.Biochemical modulation of fluorouracil:evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.J Clin Oncol 1989;7:1407-1418
  • 6[5]Piedbois P,Buyse M,Rustum Y,Machover D,Erlichman C,Carlson R,Valone F,Labianca R,Doroshow J,Petrelli N.Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer:evidence in terms of response rate.
  • 7[6]Advanced Colorectal Cancer Meta-Analysis Project.J Clin Oncol 1992; 10:896-903de Gramont A,Figer A,Seymour M,Homerin M,Hmissi A,Cassidy J,Boni C,Cortes-Funes H,Cervantes A,Freyer G,Papamichael D,Le Bail N,Louvet C,Hendler D,de Braud F,Wilson C,Morvan F,Bonetti A.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol 2000; 18:2938-2947
  • 8[7]Douillard JY,Cunningham D,Roth AD,Navarro M,James RD,Karasek P,Jandik P,Iveson T,Carmichael J,Alakl M,Gruia G,Awad L,Rougier P.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial.Lancet 2000; 355:1041-1047
  • 9[8]Goldberg RM,Sargent DJ,Morton RF,Fuchs CS,Ramanathan RK,Williamson SK,Findlay BP,Pitot HC,Alberts SR.A randomized controlled trial of fluorouracil plus leucovorin,irinotecan,and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.J Clin Oncol 2004; 22:23-30
  • 10[9]Grothey A,Sargent D.Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil,irinotecan,and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.J Clin Oncol 2005; 23:9441-9442

共引文献8

同被引文献7

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部